Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects

Phytotherapy Research

Volumn 22, Issue 4, 2008, Pages 518-523

  Belcaro, G ^a,b   Cesarone, M R ^a   Errichi, S ^a   Zulli, C ^a   Errichi, B M ^a   Vinciguerra, G ^a   Ledda, A ^a   Di Renzo, A ^a   Stuard, S ^a   Dugall, M ^a   Pellegrini, L ^a   Gizzi, G ^a   Ippolito, E ^a   Ricci, A ^a   Cacchio, M ^a   Cipollone, G ^a   Ruffini, I ^a   Fano, F ^a   Hosoi, M ^a   Rohdewald, P ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antiinflammatory agents; Edema; Joints; Muscular performance; Noninvasive investigations; Osteoarthrosis; Pain; Pycnogenol ; WOMAC

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PYCNOGENOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG USE; EVENING DOSAGE; FEMALE; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OSTEOARTHRITIS; PATIENT ASSESSMENT; PHYSICAL DISEASE BY BODY FUNCTION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREADMILL EXERCISE; TREATMENT DURATION; WALKING;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE DISTRIBUTION; ANKLE; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; EDEMA; FEMALE; FLAVONOIDS; FOOT; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 42949167288     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2376     Document Type: Article

References (18)

1. Baron G, Tubach F, Ravaud P, Logeart I, Dougados M. 2007. Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis. Arthritis Rheum 57: 633-638.
2. Belcaro G, Cesarone MR, Ricci A, Cornelli U, Rohdewald P, Ledda A. 2006. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with pycnogenol. Clin Appl Thromb Hemost 12: 440-444.
3. Belcaro G, Nicolaides AN, Veller M. 1996. Venous Disorders A Manual of Diagnosis And Treatment. Saunders: Cambridge.
4. Belcaro G, Nicolaides AN. 2001. Noninvasive Investigations in Vascular Disease. Imperial College Press: London.
5. Cesarone MR, Belcaro G, Nicolaides AN, Arkans E. 1999. The edema tester in the evaluation of swollen limbs in venous and lymphatic disease. Panminerva Med 41: 10-14.
6. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ippolito E, Scoccianti M. 2005. Prevention of edema in long flights with Pycnogenol®. Clin Appl Thromb Hemost 11: 289-294.
7. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G. 2006a. Comparison of pycnogenol and daflon in treating chronic venous insufficiency: A prospective, controlled study. Clin Appl Thromb Hemost 12: 205-212.
8. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G. 2006b. Improvement of diabetic microangiopathy with pycnogenol: a prospective, controlled study. Angiology 57: 431-436.
9. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G. 2006c. Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study. Angiology 57: 569-576.
10. Cisar P, Jany R, Vojtassák J, Rohdewald P, Durackova Z. 2006. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. J Preventive Med 2: Special issue, 58.
11. Devaraj S, Vega-López S, Kaul N, Schönlau F, Rohdewald P, Jialal I. 2002. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 37: 931-934.
12. Durackova Z, Trebaticky B, Novotny V, Zitnanova A, Breza J. 2003. Lipid metabolism and erectile function improvement by Pycnogenol®, extract from the bark of Pinus pinaster in patients suffering from erectile dysfunction - a pilot study. Nutr Res 23: 1189-1198.
13. Farid R, Mirteizi A, Mirheidari M, Rezaieyazdi S, Mansouritorghabeh H, Zibadi S, Watson RR. 2007. Pycnogenol® reduces clinical symptoms of knee osteoarthritis. Nutr Res 27: 692-697.
14. Grimm T, Chovanová Z, Muchová J, Sumegová K, Liptátková A, Duracková Z. 2006. Inhibition of NF-κB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflam 3: 1-6.
15. Rahme E, Nedjar H. 2007. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology 46: 435-438.
16. Rohdewald P. 2005. Pycnogenol®, French maritime pine bark extract. In Encyclopedia of Dietary Supplements, Coates PM, Blackman MR, Cragg G, Levine M, Moss J, White J (eds). Marcel Dekker: New York, 545-553.
17. Schäfer A, Chovanová Z, Muchová J, Sumegová K, Liptákova A, Duracková Z. 2006. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 60: 5-9.
18. Stillman MJ, Stillman MT. 2007. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway. Geriatrics 62: 26-34.